KRAS and myeloproliferative disorder: In MDS/MPN, they are frequently accompanied by other somatic mutations (EZH2, PTPN11, SETBP1, SRSF2, STAG2, N/KRAS) and they are associated with advanced disease features, such as leukocytosis or higher blast percentage [2,4,37].